I think the confusion of "up to" was from SEC.
The action notice stated: "DECN’s sales forecasts for the COVID-19 test kit that up to 525 million test kits would be sold in the first year of production."
The point I raise very early was that Mr. Berman never said anywhere that anything WOULD be sold, all was projection and expectation, plus I told the SEC investigator then what many have since posted here: "up to" is used by thousands of companies daily with no repercussions. The statement as he made it and as they referenced it can be fulfilled by selling one test kit. They know that. That's why I (along with you and others) think there is much more here than meets the eye. BP has to be terribly nervous IF there DECN's claims are credible.
From PRs:
3/11 “We anticipate the sale of 420,000,000 kits in the first full year of commercial sale.”
3/16 – “We expect the vast majority of the 420 million test kits we plan to manufacture in the first year of production will be sold to individuals for self-testing."
3/17 “We are happy to inform all interested parties that we have raised our 12-month forecast to 525 million kits.”
His final clarification was on 4/23:
"While the FDA assesses how to move forward with this technology, the company is moving to work with a large health care products distributor who has already received requests for the GenViro! Swift kits. Outlets ranging from Fortune 50 corporations to professional sports leagues have shown strong interest. The company estimates it will be asked to produce 1 million "Swift Kits" per month through the end of the year just for the "back to work" markets, based on the rapidly building demand."
Notice: 1M/month = much reduced = adjusted
estimates
anticipate
expect
plan
forecast
